3rd Quarter - Report

FAEGRE BAKER DANIELS CONSULTING for USAGAINST ALZHEIMER'S

Firm
Client
Income
$20,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

S. 1126 - Concentrating on High-Value Alzheimer's Needs to Get to an End (CHANGE) Act of 2019; HR 2283 - CHANGE Act of 2019

LobbyistCovered position, as disclosed
JOHN KEVIN BRENNAN Chief of Staff, Rep. Rosa DeLauro (D-CT); Legislative Director, Rep. Sherrod Brown (D-OH); Legislative Assistant, Rep. Tom Foglietta (D-PA)
JENNIFER DALE Scheduler, Rep. Jason Altmire (D-PA); Scheduler and Director of Operations, Rep. Mike Thompson (D-CA)
NICK MANETTO Legislative Assistant, Rep. Christopher H. Smith (R-NJ)

Contacted: Natl Institutes of Health (NIH); HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 1126 (116th), H.R. 2283 (116th)

Budget/Appropriations BUD

Fiscal Year 2020 funding for Alzheimer's disease research and policies to enhance NIH Alzheimer's research.

LobbyistCovered position, as disclosed
JOHN KEVIN BRENNAN Chief of Staff, Rep. Rosa DeLauro (D-CT); Legislative Director, Rep. Sherrod Brown (D-OH); Legislative Assistant, Rep. Tom Foglietta (D-PA)
JENNIFER DALE Scheduler, Rep. Jason Altmire (D-PA); Scheduler and Director of Operations, Rep. Mike Thompson (D-CA)
NICK MANETTO Legislative Assistant, Rep. Christopher H. Smith (R-NJ)

Contacted: SENATE; Natl Institutes of Health (NIH); HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.